Intermittent Mechanical Compression For Peripheral Arterial Disease
Phase 4
Completed
- Conditions
- Peripheral Arterial Disease
- Interventions
- Device: Intermittent Mechanical CompressionDrug: Control
- Registration Number
- NCT00855673
- Lead Sponsor
- Hospital Universitario Getafe
- Brief Summary
The study tests the use of a portable mechanical compression device (FM220, Flowmedic, USA) for the treatment of claudication and peripheral arterial disease.
Major endpoints are improved exercise tolerance and relevant blood pressure ratios
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- stable claudication with an absolute claudication distance >40 meters but <300
- resting ABI in the affected limb <0.8
Exclusion Criteria
- presence of diabetes
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Active Intermittent Mechanical Compression Active group receiving intermittent compression Control Control Standard Medical Treatment
- Primary Outcome Measures
Name Time Method exercise tolerance 3 months
- Secondary Outcome Measures
Name Time Method ankle-brachial index 3 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie intermittent mechanical compression's effect on claudication in peripheral arterial disease?
How does the Flowmedic FM220 device compare to standard-of-care treatments like cilostazol in improving exercise tolerance for PAD patients?
Are there specific biomarkers that predict response to intermittent mechanical compression therapy in peripheral arterial disease?
What are the known adverse events associated with Flowmedic's intermittent mechanical compression and how are they managed?
What combination therapies or competitor devices are being explored alongside intermittent mechanical compression for peripheral arterial disease treatment?